Form 4: OnKure Therapeutics Exec Sells Shares for Tax Withholding

Nicholas Saccomano, President and CEO of OnKure Therapeutics, Inc., reported a transaction involving the sale of Class A Common Stock to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Summary

• Nicholas Saccomano, President and CEO and Director of OnKure Therapeutics, Inc., reported a sale of 86 shares of Class A Common Stock on June 22, 2026.
• The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) under the Issuer's 2023 RSU Equity Incentive Plan.
• The weighted average sale price was $4.3963, with individual trades ranging from $4.27 to $4.54.
• Following this transaction, Saccomano beneficially owns 11,247 shares of Class A Common Stock.
• The filing also notes that Saccomano acquired 4,000 shares under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported transaction is a standard and expected event related to executive compensation and tax obligations, rather than a reflection of the company's performance or future prospects.

Positives

• The transaction was an automatic sale to cover tax obligations, indicating a standard process for equity compensation.
• The company has an active Employee Stock Purchase Plan, suggesting opportunities for employees to acquire company stock.

Negatives

• A portion of the reporting person's equity was sold, which could be perceived negatively by the market, although it was for tax purposes.

Risks

• The filing does not explicitly mention any new risks or challenges.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to RSU vesting and tax withholding, are common in the biotechnology and pharmaceutical sectors as companies utilize equity compensation to attract and retain talent. The sale of shares to cover taxes is a routine event and does not necessarily indicate a negative view of the company's prospects by management.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive for tax purposes is a routine event and is unlikely to have a significant direct impact on the share price, though it reduces the executive's direct holdings.

Next Steps

• The reporting person will continue to hold the remaining 11,247 shares of Class A Common Stock.
• The company's 2023 RSU Equity Incentive Plan and 2024 Employee Stock Purchase Plan will continue to operate as per their terms.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Nicholas Saccomano, Class A Common Stock, Employee Stock Purchase Plan